Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Breast Neoplasms 7Rectal Neoplasms 2Inflammatory Breast Neoplasms 2Colonic Neoplasms 2Malignant Solid Neoplasm 1

Interventions

Oxaliplatin 49Fluorouracil 45Leucovorin 42Capecitabine 40Irinotecan 31Bevacizumab 31Radiotherapy 24Cetuximab 23Radiation 13Panitumumab 13Folfox protocol 10Surgical Procedures, Operative 9IFL protocol 8Radiotherapy, Intensity-Modulated 6Magnetic Resonance Spectroscopy 6aflibercept 5Immunohistochemistry 5Gene Expression Profiling 5Chemotherapy, Adjuvant 5Fluorodeoxyglucose F18 4Floxuridine 4Celecoxib 4trifluridine tipiracil drug combination 3dehydroftorafur 3XELOX 3Sorafenib 3Ramucirumab 3Neoadjuvant Therapy 3Erlotinib Hydrochloride 3Drug Therapy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Rectal Neoplasms × 2C4 antibody × Clear all
NCT03365882 2026-02-10

S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery

SWOG Cancer Research Network

Phase 2 Completed
240 enrolled 14 charts
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

NCT00551421 2015-03-31

Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
17 enrolled 7 charts
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡